Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 64 от 222

Recruiting

Pilot Randomized Study for Treatment Volume De-Escalation for Spinal Metastases With Stereotactic Body Radiation Therapy

Metastases to Bone

A single centre, non-profit, randomised, unblinded pilot study on volume definition for spinal stereotactic body radiation therapy treatment. Randomization will be 1:1 between two types of SBRT treatment for spinal metastases. The statistical unit will be the individual vertebral metastasis. Multiple metastases will be randomized and evaluated independently.

Начало: 04.11.2025 Край: 04.05.2029 Възраст: от 18 г.

Italy IRCCS Sacro Cuore Don Calabria di Negrar NCT07538024

Recruiting Phase 1/2

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Glioma CNS Tumor, Adult CNS Tumor, Childhood

This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel, histology-defined cohorts (IDH-mutant glioma, other gliomas, and other CNS tumors). A pre-screening to detect DLL3 expression by IHC on archival tumor sample must be performed before the therapeutic part. Only patients with DLL3 positive tumor on IHC can be enrolled in the therapeutic part. This pre-screening must be optimally performed during the ongoing treatment line i.e. before documented progression to not delay treatment starts at time of progression. Tumor samples (surgery or biopsy specimen) will be sent to a central lab for IHC testing.

Начало: 04.11.2025 Край: 01.10.2030 Възраст: от 12 г.

France Centre Leon Berard NCT07243470

Recruiting Phase 1/2

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Obesity &Amp; Overweight

Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)

Начало: 04.11.2025 Край: 15.08.2027 Възраст: 18–65 г. Treatment

Australia Ikaria Bioscience Pty Ltd NCT07245771

Recruiting Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Alveolar Soft Part Sarcoma Metastatic Alveolar Soft Part Sarcoma Locally Advanced Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer +6

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effects. Objective: To test different doses and timing of atezolizumab for people with cancer. Eligibility: People aged 18 years and older with cancer that has spread locally or to other organs. They must be eligible for treatment with the study drug. Design: Participants will be screened. They will have blood tests and imaging scans. They will provide a sample of tissue from their tumor. Atezolizumab is administered through a tube attached to a needle inserted into a vein in the arm. Participants will take this drug alone or combined with other drugs prescribed for their care. The first 2 treatments will be done per the FDA recommended dose and schedule. Before administering the second dose of the study drug, researchers will check the level of the drug in the participant s blood. Depending on those results, their 3rd dose will be scheduled 2 to 6 weeks later. For the 3rd dose of the study drug, participants will switch to the FDA minimum dosage. Dosages of any other drugs will not change. Researchers will continue to test the levels of the drug in participants blood before each treatment for 16 weeks. After that, these levels will be tested every 3 months. Study treatment may last up to 2 years.

Начало: 04.11.2025 Край: 31.01.2028 Възраст: 18–120 г.

United States National Cancer Institute (NCI) NCT06066138

Recruiting Phase 1/2

Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Mild to Moderate Asthma

Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.

Начало: 04.11.2025 Край: 31.01.2027 Възраст: 18–65 г. Treatment

Australia, New Zealand Prana Therapies Inc NCT07245368

Recruiting

Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity

Obesity and Obesity-related Medical Conditions

The goal of this randomized trial is to: 1) investigate the immunological landscape of patients with obesity and conduct an in-depth functional characterization of their immune system; and 2) precisely define the effects of time-restricted feeding (TRF) on immune function in patients with obesity; 3) uncover the underlying mechanisms by which TRF modulates the immune system patients with obesity through a multi-omics approach. The main questions it aims to answer are: i) what is the underlying cause of impaired immunocompetence in patients with obesity? ii) how nutritional interventions improve the immune function of patients with obesity? Patients with obesity following TRF (8 h eating window ranging from 6-8 am to 14-16 pm) will be compared to patients with obesity without TRF control schedule (14h eating window ranging from 6-8 am to 8-10 pm). In addition to patients with obesity, the present study aims to recruit a group of a reference healthy group (BMI between 18.5-24.9 kg/m²) that will not receive any nutritional intervention. The following endpoints will be collected: Body weight and composition using Bioelectrical Impedance Analysis, resting energy expenditure (REE) using indirect calorimetry, blood glucose levels using a continuous glucose monitoring (CGM) device, metabolic parameters (fasting blood glucose levels, C-peptide, HbA1c, insulin, HOMA-IR, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, hepatic enzymes), and cytokine profile. Blood and stool, samples will be collected to establish metagenomic, transcriptomic, cytomic and metabolomic analyses.

Начало: 03.11.2025 Край: 15.09.2027 Възраст: 18–64 г.

France Assistance Publique - Hôpitaux de Paris NCT06899997

Recruiting Phase 2

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Still´s Disease

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease

Начало: 03.11.2025 Край: 24.05.2029 Възраст: 1–100 г.

Canada, France, Germany +5 Novartis Pharmaceuticals NCT07203001

Recruiting

Health Web Te@m (1.0) an Interprofessional Web-based Group Intervention Supporting Healthy Ageing

Healthy Older Adults

The goal of this study is to evaluate the feasibility of Health Web - Te@m 1.0 for older adults in selected primary healthcare settings in northern Sweden. More specifically, the feasibility will be assessed through the following objectives: * Explore older adults' experiences of the intervention process, acceptability, and perceptions of the value of participating in Health Web - Te@m. * Explore professionals' experiences of acceptability, value, and implementation potential of delivering Health Web - Te@m in primary healthcare settings. * Evaluate adherence to Health Web - Te@m among older adults and professionals. * Evaluate the assessments' ability to detect potential outcomes of Health Web - Te@m.

Начало: 03.11.2025 Край: 01.12.2026 Възраст: от 65 г.

Sweden Luleå Tekniska Universitet NCT07545915

Recruiting Phase 3

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Lewy body Dementia psychosis (LBDP)

Trial status: Authorised Treatment-emergent adverse events (TEAEs)

Начало: 03.11.2025 Възраст: от 18 г.

Bulgaria, Czech Republic, France +1 Acadia Pharmaceuticals Inc. 2025-521711-39-00

Recruiting Phase 2

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

Cystic Fibrosis (CF)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.

Начало: 03.11.2025 Край: 01.07.2026 Възраст: 18–65 г. Treatment

Australia, United States Sionna Therapeutics Inc. NCT07108153

Recruiting

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder Cancer Recurrent Bladder Cancer Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer Study 2 (CISTO2) has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO2 is to conduct a large prospective study that directly compares the impact of bladder sparing therapies versus bladder removal in recurrent high-grade NMIBC patients on financial toxicity, clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).

Начало: 03.11.2025 Край: 01.12.2028 Възраст: от 18 г.

United States University of Washington NCT07225127

Recruiting Phase 1

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Haematologic Neoplasms

The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.

Начало: 03.11.2025 Край: 20.10.2028 Възраст: 18–110 г. Treatment

Australia, Japan, South Korea +4 AstraZeneca NCT07064122

Recruiting Phase 2

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Smoking

This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .

Начало: 03.11.2025 Край: 01.02.2027 Възраст: 18–75 г.

China, Japan, United States Eli Lilly and Company NCT07223840

Recruiting Phase 2

Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation

Mechanical Ventilation Sedation and Analgesia Critical Care, Intensive Care

Patients with respiratory failure who require mechanical ventilation are not only at risk of death, but also of complications of prolonged ICU stay. Patients may have significant functional decline, impact in quality of life, develop psychiatric disorders and at long-term can lead to significant cost to society. Although sedation and analgesia are considered only supportive therapy, several studies have shown that in patients on mechanical ventilation, different approaches can have significant impact on patient centered outcomes. However, to date, randomized clinical trials on critically ill patients have mostly evaluated the sedative agent but not the analgesic agent. Although morphine and its derivates are the most common used opioid analgesic agents in the critical care setting, only some retrospective studies and some prospective studies compared them head-to-head (ramifentanyl versus morphine and fentanyl versus morphine). Current guidelines recommend choosing the analgesic agent based on pharmacokinectics, physician experience and side-effects profile. To evaluate the differences of two standard-of-care analgosedation agents, the FenHydro trial will be a cluster randomized, pragmatic, pilot and feasibility superiority clinical trial in mechanically ventilated patients in the ICU. The main question the study hopes to answer is whether there is any difference in morphine milligram equivalents administered during mechanical ventilation.

Начало: 03.11.2025 Край: 01.06.2026 Възраст: от 18 г.

United States Beth Israel Deaconess Medical Center NCT07224620

Recruiting

Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease

Ventricular Tachycardia Cardiomyopathies Arrhythmias, Cardiac Ventricular Arrythmia

The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are: * What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months * What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).

Начало: 03.11.2025 Край: 20.12.2027 Възраст: от 18 г. Treatment

Australia Western Sydney Local Health District NCT06360939

Recruiting

Using a Speech-Generating Device to Support Communication in Childhood Dementia

Childhood Dementia Genetic Disease Nonverbal Communication Augmentative and Alternative Communication

Individuals with childhood dementia experience loss of developmental skills and many have limited verbal speech. The aim of this clinical trial is to examine how well a speech-generating device supports the communication skills of participants with childhood dementia. The speech-generating device is a communication program loaded onto an iPad. This is a crossover trial, meaning that each participant will receive both the treatment (device) and a control (usual care; no device) phase. The order in which each participant receives the device versus the usual care (no device) will depend on which group the participant is assigned to. The changes in communication in each phase will then be compared. During the trial, participants can expect to complete a series of assessments and attend a total of 2 x 1-hour therapy session per week for 6 weeks.

Начало: 03.11.2025 Край: 01.05.2027 Възраст: 3–12 г. Supportive care

Australia Murdoch Childrens Research Institute NCT07039084

Recruiting Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast Cancer Locally Advanced Breast Cancer Metastatic Breast Cancer ER Positive Breast Cancer +1

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Начало: 03.11.2025 Край: 01.01.2032 Възраст: от 18 г. Treatment

Australia, Canada, France +13 Olema Pharmaceuticals, Inc. NCT07085767

Recruiting

Evaluation of Zygomatic Implant Placement Accuracy Using Fully Metallic vs Resin-based Static Surgical Guides in Severely Atrophic Maxilla

Atrophic Edentulous Maxilla Zygomatic Implants Guided Surgery Dental Implant +1

Some patients lose a large amount of bone in the upper jaw. When this happens, it can be difficult to place regular dental implants. In these cases, special implants called zygomatic implants can be used. These implants are longer than normal implants and are fixed in the cheekbone, which usually has enough bone to support them. They can help support fixed teeth for patients with severe bone loss in the upper jaw. Placing zygomatic implants requires careful planning and high accuracy. To help guide the surgeon during the operation, a surgical guide can be used. A surgical guide is a custom-made device that helps the surgeon place the implant in the planned position. Surgical guides can be made from different materials. The most common type is made from resin (a strong plastic material) using 3D printing. Recently, fully metallic surgical guides have been developed. These metal guides may be stronger and more stable during surgery, but it is not yet clear if they improve the accuracy of implant placement. The purpose of this study is to compare the accuracy of metal surgical guides and resin surgical guides when placing zygomatic implants in patients with severe bone loss in the upper jaw. Patients included in the study will undergo a clinical examination and a CT scan before surgery to plan the implant positions. During the surgery, each patient will receive zygomatic implants on both sides of the upper jaw. On one side, the implants will be placed using a metal surgical guide, and on the other side, they will be placed using a resin surgical guide. This allows the two types of guides to be compared in the same patient. After the surgery, another CT scan will be taken to check the final position of the implants. The planned implant position will be compared with the actual position after surgery to measure the accuracy of placement. The results of this study will help determine whether metallic surgical guides or resin surgical guides provide better accuracy when placing zygomatic implants. Participation in this study is voluntary. All patients will receive full information about the study and will sign a consent form before participating.

Начало: 03.11.2025 Край: 01.05.2026 Възраст: от 18 г.

Egypt Future University in Egypt NCT07551024

Recruiting

Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

Diabete Mellitus Retina Vein Occlusion Age Macular Degeneration

Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics through intravitreal injection. The systemic use of bevacizumab has been associated with serious conditions such as thromboembolism and bleeding. Although intravitreal bevacizumab is administered in smaller amounts and has limited systemic circulation, it requires repeated injections over a long period. These long-term intravitreal anti-VEGF therapies may lead to adverse outcomes, particularly thromboembolism, due to systemic inhibition of VEGF. However, limited information is available regarding the potential effects of this treatment on the systemic and cardiovascular systems. To evaluate this risk, the study aims to assess changes in the activities of paraoxonase 1 (PON1), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE), which are closely associated with lipid metabolism, coronary artery disease, and atherosclerosis. These enzymes are known biomarkers of cardiovascular health and play significant roles in protection against oxidative stress and inflammation. For this purpose, a case-control study is planned. Serum BChE and PON1 activities, as well as triglyceride (TG)/high-density lipoprotein (HDL) and TG/glucose ratios, will be determined in patients receiving repeated intravitreal bevacizumab injections and in control groups, and cardiovascular disease risk will be assessed. This study may help us better understand the safety profile of this treatment by revealing the effects of bevacizumab on serum enzyme activities and cardiovascular risk factors. These findings could contribute to optimizing treatment strategies in clinical practice.

Начало: 03.11.2025 Край: 10.07.2026 Възраст: 50–80 г.

Turkey (Türkiye) Ataturk University NCT07550777

Recruiting Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Neoplastic Disease Glioblastoma Glioblastoma (GBM) Glioblastoma Multiform +2

This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.

Начало: 02.11.2025 Край: 01.11.2027 Възраст: от 18 г. Treatment

Australia, Netherlands Telix Pharmaceuticals (Innovations) Pty Limited NCT07100730

1 … 62 63 64 65 66 … 222